Frontpage Slideshow | Copyright © 2006-2011 JoomlaWorks Ltd.

Get in touch

1800 437 222

Viral hepatitis (A, B & C)

Hepatitis means inflammation of the liver, and it can be caused by a virus or other non-viral causes.  The main difference between the viruses is how they are spread and the effects they have on your health.

Read more...

Prevention

There are safe and effective vaccines that protect you from getting hepatitis A and B.  While there is no vaccine for hep C, by being ‘blood aware’ you can reduce your overall chance of being exposed to the virus.

Read more...

Living with Hepatitis

People with chronic hepatitis can do a number of things to stay healthy including limiting/avoiding alcohol, reducing stress, not smoking, getting regular exercise and eating a healthy diet.

Read more...

Treatment

Effective treatment is available for both chronic hepatitis B and C.  Before you can see a liver specialist to talk about going on treatment, you need to get a referral from your GP first.

Read more...
ContentViewArticle Object
(
    [item:protected] => stdClass Object
        (
            [id] => 350
            [asset_id] => 424
            [title] => New Hep C treatment on PBS welcome - but still more to do
            [alias] => new-hep-c-treatment-on-pbs-welcome-but-still-more-to-do
            [title_alias] => 
            [introtext] => 

Media Release from Hepatitis Australia

The Pharmaceutical Benefits Scheme (PBS) listing of Viekira Pak® and Viekira Pak-RBV® from 1 May is a very welcome addition to the highly effective new generation treatment options for people living with hepatitis C.

Viekira Pak® is a new multi-drug treatment regimen for hepatitis C genotype 1, which combines paritaprevir-ritonavir, ombitasvir and dasabuvir, used with, or without, ribavirin.

It will be available on the PBS from 1 May 2016 along with the existing direct-acting antiviral medicines that were listed from March this year. Australian clinical data recently released demonstrates an overall cure rate of greater than 90% and 100% in those without cirrhosis.

We know that several thousand people have commenced treatment since 1 March. Hepatitis Australia understands that the number of people receiving treatment in March 2016 has matched, or exceeded the number of people receiving treatment during the whole of 2014.

This good news is tempered by the fact that some people living with less common hepatitis C genotypes are still desperately waiting for new treatments to become available without the terrible side-effects of the older medicine.

“I find it really heartbreaking that genotypes 4 to 6 - which make up only a very small percentage of the hep C population in Australia still can't have access to interferon free treatment. We were waiting with hope ― like everyone else ― only to be left behind again.” Facebook follower 30/3/16

There are six main genotypes (strains) of the hepatitis C virus. In Australia, the most prevalent (90%) genotypes are 1 and 3. The currently approved treatments in Australia provide a number of interferon-free options for genotypes 1, 2 and 3. Under current guidelines, people with genotypes 4, 5 and 6 still have to experience the debilitating side- effects associated with pegylated interferon.

Trials of treatment regimens that are effective across all hepatitis C genotypes (pangenotypic medicines) are continuing, but it is currently unclear how long Australians will need to wait for these to become available on the PBS. Once approved, the introduction and PBS listing of pan-genotypic medicines will be the next major step in treating and eliminating hepatitis C in Australia.

In the meantime, people with the less common genotypes ― 4, 5, or 6, can speak to their hepatitis specialist about clinical trials or early access programs being conducted by the pharmaceutical companies.

For further information please go our Hepatitis C Treatment Factsheet which can be accessed via this link: www.hepatitisaustralia.com/newtreatments

Media Contact: Helen Tyrrell 0413 454 257


Older news:

[fulltext] => [state] => 1 [mask] => 0 [catid] => 3 [created] => 2016-04-29 00:22:21 [created_by] => 66 [created_by_alias] => [modified] => 2016-04-29 00:22:50 [modified_by] => 66 [checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [publish_up] => 2016-04-29 00:22:21 [publish_down] => 0000-00-00 00:00:00 [images] => [urls] => [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [version] => 2 [parentid] => 0 [ordering] => 65 [metakey] => [metadesc] => [access] => 1 [hits] => 2385 [metadata] => JRegistry Object ( [data:protected] => stdClass Object ( [robots] => [author] => [rights] => [xreference] => ) ) [featured] => 0 [language] => * [xreference] => [category_title] => News & Events [category_alias] => news-a-events [category_access] => 1 [author] => Hepatitis Admin [contactid] => [parent_title] => General [parent_id] => 15 [parent_route] => general [parent_alias] => general [rating] => [rating_count] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [access-view] => 1 ) ) [slug] => 350:new-hep-c-treatment-on-pbs-welcome-but-still-more-to-do [catslug] => 3:news-a-events [parent_slug] => 15:general [readmore_link] => /news-media-a-events/our-news/3-news-a-events/350-new-hep-c-treatment-on-pbs-welcome-but-still-more-to-do [text] =>

Media Release from Hepatitis Australia

The Pharmaceutical Benefits Scheme (PBS) listing of Viekira Pak® and Viekira Pak-RBV® from 1 May is a very welcome addition to the highly effective new generation treatment options for people living with hepatitis C.

Viekira Pak® is a new multi-drug treatment regimen for hepatitis C genotype 1, which combines paritaprevir-ritonavir, ombitasvir and dasabuvir, used with, or without, ribavirin.

It will be available on the PBS from 1 May 2016 along with the existing direct-acting antiviral medicines that were listed from March this year. Australian clinical data recently released demonstrates an overall cure rate of greater than 90% and 100% in those without cirrhosis.

We know that several thousand people have commenced treatment since 1 March. Hepatitis Australia understands that the number of people receiving treatment in March 2016 has matched, or exceeded the number of people receiving treatment during the whole of 2014.

This good news is tempered by the fact that some people living with less common hepatitis C genotypes are still desperately waiting for new treatments to become available without the terrible side-effects of the older medicine.

“I find it really heartbreaking that genotypes 4 to 6 - which make up only a very small percentage of the hep C population in Australia still can't have access to interferon free treatment. We were waiting with hope ― like everyone else ― only to be left behind again.” Facebook follower 30/3/16

There are six main genotypes (strains) of the hepatitis C virus. In Australia, the most prevalent (90%) genotypes are 1 and 3. The currently approved treatments in Australia provide a number of interferon-free options for genotypes 1, 2 and 3. Under current guidelines, people with genotypes 4, 5 and 6 still have to experience the debilitating side- effects associated with pegylated interferon.

Trials of treatment regimens that are effective across all hepatitis C genotypes (pangenotypic medicines) are continuing, but it is currently unclear how long Australians will need to wait for these to become available on the PBS. Once approved, the introduction and PBS listing of pan-genotypic medicines will be the next major step in treating and eliminating hepatitis C in Australia.

In the meantime, people with the less common genotypes ― 4, 5, or 6, can speak to their hepatitis specialist about clinical trials or early access programs being conducted by the pharmaceutical companies.

For further information please go our Hepatitis C Treatment Factsheet which can be accessed via this link: www.hepatitisaustralia.com/newtreatments

Media Contact: Helen Tyrrell 0413 454 257


Older news:

[event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) ) [params:protected] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [page_heading] => Latest News ) ) [print:protected] => [state:protected] => JObject Object ( [_errors:protected] => Array ( ) [task] => [parameters.menu] => JRegistry Object ( [data:protected] => stdClass Object ( [show_title] => [link_titles] => [show_intro] => [show_category] => [link_category] => [show_parent_category] => [link_parent_category] => [show_author] => [link_author] => [show_create_date] => [show_modify_date] => [show_publish_date] => [show_item_navigation] => [show_vote] => [show_icons] => [show_print_icon] => [show_email_icon] => [show_hits] => [show_noauth] => [urls_position] => [menu-anchor_title] => [menu-anchor_css] => [menu_image] => [menu_text] => 1 [page_title] => [show_page_heading] => 0 [page_heading] => [pageclass_sfx] => [menu-meta_description] => [menu-meta_keywords] => [robots] => [secure] => 0 ) ) [article.id] => 350 [list.offset] => 0 [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [page_heading] => Latest News ) ) [filter.published] => 1 [filter.archived] => 2 [filter.language] => ) [user:protected] => JUser Object ( [isRoot:protected] => [id] => 0 [name] => [username] => [email] => [password] => [password_clear] => [usertype] => [block] => [sendEmail] => 0 [registerDate] => [lastvisitDate] => [activation] => [params] => [groups] => Array ( ) [guest] => 1 [lastResetTime] => [resetCount] => [_params:protected] => JRegistry Object ( [data:protected] => stdClass Object ( ) ) [_authGroups:protected] => Array ( [0] => 1 ) [_authLevels:protected] => Array ( [0] => 1 [1] => 1 ) [_authActions:protected] => [_errorMsg:protected] => [_errors:protected] => Array ( ) [aid] => 0 ) [_name:protected] => article [_models:protected] => Array ( [article] => ContentModelArticle Object ( [_context:protected] => com_content.article [_item:protected] => Array ( [350] => stdClass Object ( [id] => 350 [asset_id] => 424 [title] => New Hep C treatment on PBS welcome - but still more to do [alias] => new-hep-c-treatment-on-pbs-welcome-but-still-more-to-do [title_alias] => [introtext] =>

Media Release from Hepatitis Australia

The Pharmaceutical Benefits Scheme (PBS) listing of Viekira Pak® and Viekira Pak-RBV® from 1 May is a very welcome addition to the highly effective new generation treatment options for people living with hepatitis C.

Viekira Pak® is a new multi-drug treatment regimen for hepatitis C genotype 1, which combines paritaprevir-ritonavir, ombitasvir and dasabuvir, used with, or without, ribavirin.

It will be available on the PBS from 1 May 2016 along with the existing direct-acting antiviral medicines that were listed from March this year. Australian clinical data recently released demonstrates an overall cure rate of greater than 90% and 100% in those without cirrhosis.

We know that several thousand people have commenced treatment since 1 March. Hepatitis Australia understands that the number of people receiving treatment in March 2016 has matched, or exceeded the number of people receiving treatment during the whole of 2014.

This good news is tempered by the fact that some people living with less common hepatitis C genotypes are still desperately waiting for new treatments to become available without the terrible side-effects of the older medicine.

“I find it really heartbreaking that genotypes 4 to 6 - which make up only a very small percentage of the hep C population in Australia still can't have access to interferon free treatment. We were waiting with hope ― like everyone else ― only to be left behind again.” Facebook follower 30/3/16

There are six main genotypes (strains) of the hepatitis C virus. In Australia, the most prevalent (90%) genotypes are 1 and 3. The currently approved treatments in Australia provide a number of interferon-free options for genotypes 1, 2 and 3. Under current guidelines, people with genotypes 4, 5 and 6 still have to experience the debilitating side- effects associated with pegylated interferon.

Trials of treatment regimens that are effective across all hepatitis C genotypes (pangenotypic medicines) are continuing, but it is currently unclear how long Australians will need to wait for these to become available on the PBS. Once approved, the introduction and PBS listing of pan-genotypic medicines will be the next major step in treating and eliminating hepatitis C in Australia.

In the meantime, people with the less common genotypes ― 4, 5, or 6, can speak to their hepatitis specialist about clinical trials or early access programs being conducted by the pharmaceutical companies.

For further information please go our Hepatitis C Treatment Factsheet which can be accessed via this link: www.hepatitisaustralia.com/newtreatments

Media Contact: Helen Tyrrell 0413 454 257


Older news:

[fulltext] => [state] => 1 [mask] => 0 [catid] => 3 [created] => 2016-04-29 00:22:21 [created_by] => 66 [created_by_alias] => [modified] => 2016-04-29 00:22:50 [modified_by] => 66 [checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [publish_up] => 2016-04-29 00:22:21 [publish_down] => 0000-00-00 00:00:00 [images] => [urls] => [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [version] => 2 [parentid] => 0 [ordering] => 65 [metakey] => [metadesc] => [access] => 1 [hits] => 2385 [metadata] => JRegistry Object ( [data:protected] => stdClass Object ( [robots] => [author] => [rights] => [xreference] => ) ) [featured] => 0 [language] => * [xreference] => [category_title] => News & Events [category_alias] => news-a-events [category_access] => 1 [author] => Hepatitis Admin [contactid] => [parent_title] => General [parent_id] => 15 [parent_route] => general [parent_alias] => general [rating] => [rating_count] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [access-view] => 1 ) ) [slug] => 350:new-hep-c-treatment-on-pbs-welcome-but-still-more-to-do [catslug] => 3:news-a-events [parent_slug] => 15:general [readmore_link] => /news-media-a-events/our-news/3-news-a-events/350-new-hep-c-treatment-on-pbs-welcome-but-still-more-to-do [text] =>

Media Release from Hepatitis Australia

The Pharmaceutical Benefits Scheme (PBS) listing of Viekira Pak® and Viekira Pak-RBV® from 1 May is a very welcome addition to the highly effective new generation treatment options for people living with hepatitis C.

Viekira Pak® is a new multi-drug treatment regimen for hepatitis C genotype 1, which combines paritaprevir-ritonavir, ombitasvir and dasabuvir, used with, or without, ribavirin.

It will be available on the PBS from 1 May 2016 along with the existing direct-acting antiviral medicines that were listed from March this year. Australian clinical data recently released demonstrates an overall cure rate of greater than 90% and 100% in those without cirrhosis.

We know that several thousand people have commenced treatment since 1 March. Hepatitis Australia understands that the number of people receiving treatment in March 2016 has matched, or exceeded the number of people receiving treatment during the whole of 2014.

This good news is tempered by the fact that some people living with less common hepatitis C genotypes are still desperately waiting for new treatments to become available without the terrible side-effects of the older medicine.

“I find it really heartbreaking that genotypes 4 to 6 - which make up only a very small percentage of the hep C population in Australia still can't have access to interferon free treatment. We were waiting with hope ― like everyone else ― only to be left behind again.” Facebook follower 30/3/16

There are six main genotypes (strains) of the hepatitis C virus. In Australia, the most prevalent (90%) genotypes are 1 and 3. The currently approved treatments in Australia provide a number of interferon-free options for genotypes 1, 2 and 3. Under current guidelines, people with genotypes 4, 5 and 6 still have to experience the debilitating side- effects associated with pegylated interferon.

Trials of treatment regimens that are effective across all hepatitis C genotypes (pangenotypic medicines) are continuing, but it is currently unclear how long Australians will need to wait for these to become available on the PBS. Once approved, the introduction and PBS listing of pan-genotypic medicines will be the next major step in treating and eliminating hepatitis C in Australia.

In the meantime, people with the less common genotypes ― 4, 5, or 6, can speak to their hepatitis specialist about clinical trials or early access programs being conducted by the pharmaceutical companies.

For further information please go our Hepatitis C Treatment Factsheet which can be accessed via this link: www.hepatitisaustralia.com/newtreatments

Media Contact: Helen Tyrrell 0413 454 257


Older news:

[event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) ) ) [__state_set:protected] => 1 [_db:protected] => JDatabaseMySQLi Object ( [name] => mysqli [nameQuote:protected] => ` [nullDate:protected] => 0000-00-00 00:00:00 [dbMinimum:protected] => 5.0.4 [_database:JDatabase:private] => hepqld_joomla [connection:protected] => mysqli Object ( [affected_rows] => 1 [client_info] => mysqlnd 5.0.11-dev - 20120503 - $Id: 76b08b24596e12d4553bd41fc93cccd5bac2fe7a $ [client_version] => 50011 [connect_errno] => 0 [connect_error] => [errno] => 0 [error] => [error_list] => Array ( ) [field_count] => 0 [host_info] => Localhost via UNIX socket [info] => Rows matched: 1 Changed: 1 Warnings: 0 [insert_id] => 0 [server_info] => 5.6.37 [server_version] => 50637 [stat] => Uptime: 2279123 Threads: 1 Questions: 179927832 Slow queries: 56 Opens: 11318169 Flush tables: 1 Open tables: 2000 Queries per second avg: 78.946 [sqlstate] => 00000 [protocol_version] => 10 [thread_id] => 2952067 [warning_count] => 0 ) [count:protected] => 0 [cursor:protected] => 1 [debug:protected] => [limit:protected] => 0 [log:protected] => Array ( ) [offset:protected] => 0 [sql:protected] => UPDATE #__content SET hits = hits + 1 WHERE id = 350 [tablePrefix:protected] => j25_ [utf:protected] => 1 [errorNum:protected] => 0 [errorMsg:protected] => [hasQuoted:protected] => [quoted:protected] => Array ( ) ) [name:protected] => article [option:protected] => com_content [state:protected] => JObject Object ( [_errors:protected] => Array ( ) [task] => [parameters.menu] => JRegistry Object ( [data:protected] => stdClass Object ( [show_title] => [link_titles] => [show_intro] => [show_category] => [link_category] => [show_parent_category] => [link_parent_category] => [show_author] => [link_author] => [show_create_date] => [show_modify_date] => [show_publish_date] => [show_item_navigation] => [show_vote] => [show_icons] => [show_print_icon] => [show_email_icon] => [show_hits] => [show_noauth] => [urls_position] => [menu-anchor_title] => [menu-anchor_css] => [menu_image] => [menu_text] => 1 [page_title] => [show_page_heading] => 0 [page_heading] => [pageclass_sfx] => [menu-meta_description] => [menu-meta_keywords] => [robots] => [secure] => 0 ) ) [article.id] => 350 [list.offset] => 0 [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [page_heading] => Latest News ) ) [filter.published] => 1 [filter.archived] => 2 [filter.language] => ) [event_clean_cache:protected] => onContentCleanCache [_errors:protected] => Array ( ) ) ) [_basePath:protected] => /home/hepqld/public_html/components/com_content [_defaultModel:protected] => article [_layout:protected] => default [_layoutExt:protected] => php [_layoutTemplate:protected] => _ [_path:protected] => Array ( [template] => Array ( [0] => /home/hepqld/public_html/templates/if_960_j25/html/com_content/article/ [1] => /home/hepqld/public_html/components/com_content/views/article/tmpl/ ) [helper] => Array ( [0] => /home/hepqld/public_html/components/com_content/helpers/ ) ) [_template:protected] => /home/hepqld/public_html/templates/if_960_j25/html/com_content/article/default.php [_output:protected] => [_escape:protected] => htmlspecialchars [_charset:protected] => UTF-8 [_errors:protected] => Array ( ) [baseurl] => [document] => JDocumentHTML Object ( [_links] => Array ( ) [_custom] => Array ( ) [template] => [baseurl] => [params] => [_file] => [_template:protected] => [_template_tags:protected] => Array ( ) [_caching:protected] => [title] => New Hep C treatment on PBS welcome - but still more to do [description] => Hepatitis Queensland [link] => [base] => http://www.hepqld.asn.au/news-media-a-events/our-news/3-news-a-events/350-new-hep-c-treatment-on-pbs-welcome-but-still-more-to-do [language] => en-gb [direction] => ltr [_generator] => Joomla! - Open Source Content Management [_mdate] => [_tab] => [_lineEnd] => [_charset] => utf-8 [_mime] => text/html [_namespace] => [_profile] => [_scripts] => Array ( [/media/system/js/mootools-core.js] => Array ( [mime] => text/javascript [defer] => [async] => ) [/media/system/js/core.js] => Array ( [mime] => text/javascript [defer] => [async] => ) [/media/system/js/caption.js] => Array ( [mime] => text/javascript [defer] => [async] => ) ) [_script] => Array ( [text/javascript] => window.addEvent('load', function() { new JCaption('img.caption'); }); ) [_styleSheets] => Array ( ) [_style] => Array ( ) [_metaTags] => Array ( [http-equiv] => Array ( [content-type] => text/html ) [standard] => Array ( [keywords] => Hepatitis Queensland [rights] => [author] => Hepatitis Admin ) ) [_engine] => [_type] => html [_errors:protected] => Array ( ) ) [pageclass_sfx] => )

New Hep C treatment on PBS welcome - but still more to do

Media Release from Hepatitis Australia

The Pharmaceutical Benefits Scheme (PBS) listing of Viekira Pak® and Viekira Pak-RBV® from 1 May is a very welcome addition to the highly effective new generation treatment options for people living with hepatitis C.

Viekira Pak® is a new multi-drug treatment regimen for hepatitis C genotype 1, which combines paritaprevir-ritonavir, ombitasvir and dasabuvir, used with, or without, ribavirin.

It will be available on the PBS from 1 May 2016 along with the existing direct-acting antiviral medicines that were listed from March this year. Australian clinical data recently released demonstrates an overall cure rate of greater than 90% and 100% in those without cirrhosis.

We know that several thousand people have commenced treatment since 1 March. Hepatitis Australia understands that the number of people receiving treatment in March 2016 has matched, or exceeded the number of people receiving treatment during the whole of 2014.

This good news is tempered by the fact that some people living with less common hepatitis C genotypes are still desperately waiting for new treatments to become available without the terrible side-effects of the older medicine.

“I find it really heartbreaking that genotypes 4 to 6 - which make up only a very small percentage of the hep C population in Australia still can't have access to interferon free treatment. We were waiting with hope ― like everyone else ― only to be left behind again.” Facebook follower 30/3/16

There are six main genotypes (strains) of the hepatitis C virus. In Australia, the most prevalent (90%) genotypes are 1 and 3. The currently approved treatments in Australia provide a number of interferon-free options for genotypes 1, 2 and 3. Under current guidelines, people with genotypes 4, 5 and 6 still have to experience the debilitating side- effects associated with pegylated interferon.

Trials of treatment regimens that are effective across all hepatitis C genotypes (pangenotypic medicines) are continuing, but it is currently unclear how long Australians will need to wait for these to become available on the PBS. Once approved, the introduction and PBS listing of pan-genotypic medicines will be the next major step in treating and eliminating hepatitis C in Australia.

In the meantime, people with the less common genotypes ― 4, 5, or 6, can speak to their hepatitis specialist about clinical trials or early access programs being conducted by the pharmaceutical companies.

For further information please go our Hepatitis C Treatment Factsheet which can be accessed via this link: www.hepatitisaustralia.com/newtreatments

Media Contact: Helen Tyrrell 0413 454 257


Older news:

© copyright 2013 | All Rights Reserved | Website design Brisbane by iFactory